Discovery Oncology @Merck prev: Postdoc @MSKCancerCenter Ph.D. in Cancer Biology @StanfordMed Views expressed are my own and do not reflect those of my employer
1/ Thrilled to share our latest story on how nutrient availability regulates chromatin & estrogen receptor signaling in breast cancer! This is the 2nd paper from my PhD thesis in the labs of @warburg_ye and Erinn Rankin. https://t.co/ZhAiswQZXx
a 🧵:
Cancer #vaccines show real promise, especially for hard-to-treat cancers. As Dr. Catherine Wu presented at #NCAB, a cancer vaccine program is now underway with @FNIH_Org to advance promising cancer vaccine technologies through rigorous clinical trials.
Although cancer is a common cause of death in domestic cats, little is known about the range of cancer genes in cat tumors, and how this range might compare with the oncogenome in people.
Now, researchers in Science have sequenced cancer genes in 493 samples from 13 different types of feline cancer and matched healthy control tissue, gaining a clearer picture of the cat oncogenome and comparing the genes to known cancer-causing mutations in humans.
Learn more: https://t.co/7HCpsZjVO2
To my immunologist and biomedicine colleagues —at the very least, for making scientific illustrations that are spot on... from your own PDFs or summaries of the literature, I've yet to see anything better.
DeepWriter is not an LLM itself- it sits on top of other LLMs and does the agentic work (right now it uses Gemini 2.5, but can use Gemini 3 or other LLMs at some point, I understand).
For reports and work I do, it's better than any of the "AI Scientists" I've seen so far. And the great thing is... as other LLMs improve, the DeepWriter overlay improves.
And this is just for science. I've used it for many other things as well. It's fantastic.
If you are a VC or seed fund, I'd seriously look at these guys.
Public service announcement —I hold no equity or monetary-compensated position with DeepWriter, but I have been advising them on how to nudge it toward better-written reports. The illustration work they did shocked me at how accurate it can be. I want them to succeed because I can already see how essential what they have is to my work. The illustration below is from a prompt I asked them to generate about tertiary lymphoid structures. I've used their illustrations in several of my recent biomedical talks.
Our group leader, Prof. Vousden, has co-authored a new textbook on cancer metabolism with Prof. Navdeep Chandel and Prof. Ralph DeBerardinis. Check it out! https://t.co/E0hYlDvyBQ
Check out our recent study showing how to re-activate estrogen responses in originally hormone low/negative breast cancer cells! Shoutout to the amazing @DeeptimanChatt2 @CicconeMichael @anandan_dhivyaa! https://t.co/jL6kNPDHuD
🎉 Our new paper is out in PNAS!
We show that combining retinoic acid (RA) with a mitochondrial uncoupler restores both mitochondrial quantity & quality, reverses the Warburg effect, and drives neuroblastoma differentiation. https://t.co/yObcZF3IiQ
#Throwback
COMMENT | KS Lee, X Su & T Huan
Metabolites are not genes — avoiding the misuse of pathway analysis in metabolomics
https://t.co/YlaTvcsefi
Pretty cool paper showing oncometabolite production by serine synthesis pathway via PHGDH in adipocytes. Unclear how mito dysfunction produces D2HG, rescue experiment with lbnox or LoF targeting integrated stress response would be informative
Can an AI model predict perfectly and still have a terrible world model?
What would that even mean?
Our new ICML paper formalizes these questions
One result tells the story: A transformer trained on 10M solar systems nails planetary orbits. But it botches gravitational laws 🧵
“A dream come true”: A child walks again after breakthrough treatment for a rare genetic disorder—thanks in part to NIH-funded research.
Scientists at @nyulangone discovered that a CoQ10 precursor can help brain cells restore energy production, offering new hope for families battling devastating conditions.
Read here for more on this life changing treatment: https://t.co/axbGGoMO3u
🚨New preprint
We uncovered a dose-dependent biphasic effect of Niclosamide:
✅Low dose: promotes mitochondrial uncoupling
❌High dose: inhibits mitochondria
This duality narrows its therapeutic window.
So—we designed next-gen analogs with expanded efficacy and reduced toxicity!
🚨Postdoctoral position available now! 🚨We have an immediate fully funded position available in cardiac metabolism. We are looking for a highly motivated person to lead our animal model work in oxidative metabolism in heart! Pay is competitive with benefits offered. 1/2
@MariosGeorgakis Was discussing this paper at dinner last night and it’s almost as if, agnostic to exercise status, the data are trimodal. Would be interesting to see what’s the real driver here 😂